These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 36901832)

  • 21. Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach.
    Parvez MSA; Karim MA; Hasan M; Jaman J; Karim Z; Tahsin T; Hasan MN; Hosen MJ
    Int J Biol Macromol; 2020 Nov; 163():1787-1797. PubMed ID: 32950529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive Consensus Analysis of SARS-CoV-2 Drug Repurposing Campaigns.
    Mslati H; Gentile F; Perez C; Cherkasov A
    J Chem Inf Model; 2021 Aug; 61(8):3771-3788. PubMed ID: 34313439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Computational Insights on the Potential of Some NSAIDs for Treating COVID-19: Priority Set and Lead Optimization.
    Abo Elmaaty A; Hamed MIA; Ismail MI; B Elkaeed E; S Abulkhair H; Khattab M; Al-Karmalawy AA
    Molecules; 2021 Jun; 26(12):. PubMed ID: 34205704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-based virtual screening, in silico docking, ADME properties prediction and molecular dynamics studies for the identification of potential inhibitors against SARS-CoV-2 M
    Mohan A; Rendine N; Mohammed MKS; Jeeva A; Ji HF; Talluri VR
    Mol Divers; 2022 Jun; 26(3):1645-1661. PubMed ID: 34480682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of promising antiviral drug candidates against non-structural protein 15 (NSP15) from SARS-CoV-2: an
    Khan RJ; Jha RK; Singh E; Jain M; Amera GM; Singh RP; Muthukumaran J; Singh AK
    J Biomol Struct Dyn; 2022 Jan; 40(1):438-448. PubMed ID: 32885740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
    Li Z; Li X; Huang YY; Wu Y; Liu R; Zhou L; Lin Y; Wu D; Zhang L; Liu H; Xu X; Yu K; Zhang Y; Cui J; Zhan CG; Wang X; Luo HB
    Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27381-27387. PubMed ID: 33051297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simultaneous Inhibition of SARS-CoV-2 Entry Pathways by Cyclosporine.
    Prasad K; Ahamad S; Kanipakam H; Gupta D; Kumar V
    ACS Chem Neurosci; 2021 Mar; 12(5):930-944. PubMed ID: 33606519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL
    Koulgi S; Jani V; Uppuladinne M; Sonavane U; Nath AK; Darbari H; Joshi R
    J Biomol Struct Dyn; 2021 Sep; 39(15):5735-5755. PubMed ID: 32679006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An Updated Review of Computer-Aided Drug Design and Its Application to COVID-19.
    Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
    Biomed Res Int; 2021; 2021():8853056. PubMed ID: 34258282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular Binding Mechanism and Pharmacology Comparative Analysis of Noscapine for Repurposing against SARS-CoV-2 Protease.
    Kumar N; Sood D; van der Spek PJ; Sharma HS; Chandra R
    J Proteome Res; 2020 Nov; 19(11):4678-4689. PubMed ID: 32786685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus.
    Prashantha CN; Gouthami K; Lavanya L; Bhavanam S; Jakhar A; Shakthiraju RG; Suraj V; Sahana KV; Sujana HS; Guruprasad NM; Ramachandra R
    J Mol Graph Model; 2021 Jan; 102():107769. PubMed ID: 33152616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive analyses of bioinformatics applications in the fight against COVID-19 pandemic.
    Ma L; Li H; Lan J; Hao X; Liu H; Wang X; Huang Y
    Comput Biol Chem; 2021 Dec; 95():107599. PubMed ID: 34773807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proteomics advances towards developing SARS-CoV-2 therapeutics using in silico drug repurposing approaches.
    Mukherjee A; Verma A; Bihani S; Burli A; Mantri K; Srivastava S
    Drug Discov Today Technol; 2021 Dec; 39():1-12. PubMed ID: 34906319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Computational studies on phylogeny and drug designing using molecular simulations for COVID-19.
    Nabi F; Ahmad O; Khan YA; Nabi A; Md Amiruddin H; Abul Qais F; Masroor A; Hisamuddin M; Uversky VN; Khan RH
    J Biomol Struct Dyn; 2022; 40(21):10753-10762. PubMed ID: 34278954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study.
    Hosseini FS; Amanlou M
    Life Sci; 2020 Oct; 258():118205. PubMed ID: 32777300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of New Hydroxyethylamine Analogs against 3CL
    Kumar S; Sharma PP; Shankar U; Kumar D; Joshi SK; Pena L; Durvasula R; Kumar A; Kempaiah P; Poonam ; Rathi B
    J Chem Inf Model; 2020 Dec; 60(12):5754-5770. PubMed ID: 32551639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2.
    Tripathi PK; Upadhyay S; Singh M; Raghavendhar S; Bhardwaj M; Sharma P; Patel AK
    Int J Biol Macromol; 2020 Dec; 164():2622-2631. PubMed ID: 32853604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic.
    Fakhar Z; Faramarzi B; Pacifico S; Faramarzi S
    J Biomol Struct Dyn; 2021 Oct; 39(16):6171-6183. PubMed ID: 32741312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
    Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
    J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.